stockportfolio.pro
Stocks / GMAB vs NBIX
GMAB vs NBIX
Genmab A/S and Neurocrine Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Genmab A/S (GMAB) | Neurocrine Biosciences, Inc. (NBIX) | |
|---|---|---|
| Market cap | $15.3B | $16.3B |
| Revenue (latest FY) | $3.72B | $2.86B |
| Net income (latest FY) | $963.00M | $478.60M |
| Revenue growth (5y CAGR) | 21.2% | 22.3% |
| Net margin | 25.9% | 16.7% |
| Return on equity | 16.5% | 14.7% |
| P/E ratio | 19.1 | 25.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 4 | 8 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GMAB — free Open NBIX — freeFrequently asked questions
Which is bigger, GMAB or NBIX?
Neurocrine Biosciences, Inc. is larger by market capitalization — $16.3B versus $15.3B.
Which grows faster, GMAB or NBIX?
Over the last five fiscal years, Neurocrine Biosciences, Inc. grew revenue faster — 22.3%/yr versus 21.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.